One day after a federal advisory panel expressed safety concerns about GlaxoSmithKline's diabetes drug Avandia, the Baylor College of Medicine said on Thursday that it is considering whether to penalize an assistant professor who apparently allowed…
This content is available exclusively to Chronicle subscribers
Already a subscriber?
Log in now
Not a subscriber yet?
Subscribe now for instant access to this article and thousands of others, data tables, and interactive charts — all available exclusively for Chronicle subscribers. Plus your subscription includes weekly print or digital delivery of The Chronicle and The Review and the Chronicle iPad® Edition.Subscribe Today